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The purpose of this study was to investigate antiproliferative activity of bonediol, an alkyl catechol isolated from the Mayan
medicinal plant Bonellia macrocarpa. Bonediol was assessed for growth inhibition of androgen-sensitive (LNCaP), androgeninsensitive (PC-3), and metastatic androgen-insensitive (PC-3M) human prostate tumor cells; toxicity on normal cell line (HEK
293) was also evaluated. Hedgehog pathway was evaluated and competitive 3H-estradiol ligand binding assay was performed.
Additionally, antioxidant activity on Nrf2-ARE pathway was evaluated. Bonediol induced a growth inhibition on prostate cancer
cell lines (IC50 from 8.5 to 20.6 𝜇M). Interestingly, bonediol binds to both estrogen receptors (ER𝛼 (2.5 𝜇M) and ER𝛽 (2.1 𝜇M)) and
displaces the native ligand E2 (17𝛽-estradiol). No significant activity was found in the Hedgehog pathway. Additionally, activity of
bonediol on Nrf2-ARE pathway suggested that bonediol could induce oxidative stress and activation of detoxification enzymes at
1 𝜇M (3.8-fold). We propose that the compound bonediol may serve as a potential chemopreventive treatment with therapeutic
potential against prostate cancer.

1. Introduction
Prostate cancer is the second most frequently diagnosed
cancer and the sixth leading cause of cancer death in males.
Approximately, one man in five will be diagnosed with
prostate cancer during his lifetime, and 1 man in 33 will die
of this disease [1]. Treatment for this disease may include
radiation therapy and androgen suppression; surgery and/or
chemotherapy are often used. However, adverse effects have
been described, decreasing the quality of life of patients [2].
Furthermore, in 15% of the patients, the cancer recurs within
a few years as an advanced “hormone-refractory” and often
metastatic disease. For these patients, there are few treatment
options available [3], and the 5-year survival rate decreases to
28% [4].

Chemotherapy is a good option for the treatment
of hormone-independent and hormone-dependent prostate
cancer; however, few therapies in clinical phase of development are available [5]. In addition, some cancers have
proven to be resistant to chemotherapy drugs [6]. Therefore,
identification of new drugs for prostate cancer treatment has
significant clinical implications.
Currently one of the signaling pathways that has been of
great interest because of its importance in the development
and progression of prostate cancer is the sonic Hedgehog (Shh) signaling pathway. The Shh pathway involves
the autocleavage of full length Shh into an active 20 kD
N-terminal fragment (ShhN), which binds to its 12-pass
transmembrane receptor, Patched (Ptc1), reversing (relieving) its inhibitory effect on Smoothened (Smo). In prostate
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cancer, Shh pathway can produce malignant transformation
of primitive prostate epithelial progenitor cells; this may be
initiated by trapping of a normal stem cell in a Shh-dependent
state of continuous renewal, which promotes tumor growth
[7–10].
The estrogen and Hedgehog signaling pathways are
crucial for physiological proliferation, differentiation, and
development of the mammary and prostate glands [11, 12].
It has also been found that activation of both Shh and
ER𝛼 can lead to the growth of cancerous tumors (insert
references here that show Shh and ERa in breast and prostate
cancer). Moreover studies suggest that ER𝛼 regulates the Shh
pathway and promotes cancer development [13–17]. Recently
a study using in vitro and in vivo models suggested estrogen,
mediated through ER𝛼 and ER𝛽, could induce carcinogenesis
and various types of toxicity in a normal prostate [18].
Investigations searching for new compounds that can inhibit
the Hedgehog pathway and regulate the ERs to treat or
prevent prostate cancer could have significant implications
[19, 20].
A direct relationship between an increase in reactive
oxygen species (ROS) and the induction of the Shh pathway
has also been documented. This induction promotes the
expression of the antiapoptotic gene Bcl-2 and inhibits the
expression of the proapoptotic gene Bax [21]. In addition,
Paschos et al. [22] suggest that androgens and estrogen play
an important role in the generation of reactive oxygen species
leading to the progression of prostate cancer and that the
antioxidant activity of certain small molecules may prevent
the progression of prostate cancer. NF-E2 Related Factor
2 (Nfr2) is an important transcription factor responsible
for stimulating the transcription of genes in response to
oxidative or electrophilic stress [23]. This process involves
the binding of Nrf2 with Maf protein in the nucleus to form
a heterodimer, subsequently interacting with antioxidant
responsive element (ARE) to activate gene transcription [24].
The Nfr2-ARE pathway induces transcription of antioxidant
proteins and phase II detoxifying enzymes, which are important for protection of cells against ROS damage [23]. Thus this
pathway may serve as a marker of oxidative stress damage.
The three ERs family members, ER𝛼, ER𝛽, and ER𝛾, play a
novel functional role in the inhibitor of Nrf2 transcriptional
activity. It is also the modulation of ER𝛼 and ER𝛽 that may
be useful as a therapeutic target in cancer chemoprevention studies or for the development of selective estrogen
receptor modulators with a lower risk of causing cancer
[25–28].
In our continuous effort to search for novel anticancer
agents from Mayan medicinal plants of the Yucatan peninsula, we recently isolated a novel compound from the
medicinal plant Bonellia macrocarpa (Cavanilles) Ståhl and
Källersjö. This new alkyl catechol, called bonediol, has been
demonstrated to have interesting antiproliferative activities in
vitro on cancer cell lines [29]. Accordingly, this study evaluated the antiproliferative properties of bonediol in various
lines of prostate cancer and also explored its effect on the
Shh signaling pathway, interactions with the Nrf2 antioxidant
response element, and potential binding to estrogen receptors
(ER𝛼 and ER𝛽).
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2. Material and Methods
2.1. Isolation of Bonediol. Root bark of B. macrocarpa was
collected from Telchac Puerto, Yucatan (Mexico). The plant
material was identified and authenticated by taxonomists
from the Department of Natural Resources of the Scientific
Research Center of Yucatan (CICY). Specimens under the
voucher number P. Simá 2979 were deposited at CICY’s
U Najil Tikin Xiw herbarium. The obtaining and characterization of the compound were performed as previously
described [29]. The pure compound was dissolved in DMSO
and stored at −20∘ C.
2.2. Cell Culture. Cell lines of human prostate cancer adenocarcinoma (PC-3), a metastatic variant of PC-3 (PC-3M),
hormone sensitive human prostate carcinoma (LNCaP), and
one normal human cell line (HEK-293) were obtained from
the American Type Culture Collection (ATCC). Shh Light
II (JHU-68) and COS-1 cells lines were used to evaluate
Shh and Nrf2-ARE pathways, respectively. The cells line PC3 was propagated in F-12K medium (Gibco) and LNCaP
in RPMI-1640 medium (Gibco). COS-1, HEK-293, and PC3M cells lines were propagated in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco). Shh Light II cells were
maintained in DMEM containing 4 mmol/L of L-glutamine
adjusted with 1.5 g/L sodium bicarbonate and 4.5 g/L glucose,
supplemented with 0.4 mg/mL G-418 and 0.15 mg/mL zeocin
(Invitrogen). All cell lines were cultured in sterile Costar T75
flasks containing fetal bovine serum (10% v/v), 100 U/mL
penicillin G, and 100 mg/mL streptomycin at 37∘ C under a
humid atmosphere containing 5% CO2 .
2.3. Antiproliferative Activity. Cells were cultured in 96-well
plates at a concentration of 5 × 104 cells per well; after being
cultured for 24 h at 37∘ C in an atmosphere of 5% CO2 (95%
humidity) cells were incubated with appropriate dilutions of
the test compound for 48 h. The growth inhibition of the
cell lines was evaluated by the sulforhodamine B method
[30]. Results are expressed as the concentration of agent
that reduces cell growth by 50% (IC50 ). Docetaxel was used
as a positive control. All determinations were performed
in triplicate. In addition, the degree of toxicity to normal
cells was evaluated, by determining the selectivity index (SI)
[31].
2.4. Assay of Inhibition from Hedgehog Pathway. Gli activity in the Shh Light II cell line was assayed after 48 h
of treatment with bonediol compound in phenol red-free
DMEM supplemented with 0.5% charcoal-stripped serum
using the Dual Luciferase Reporter Assay System (Promega).
Each experiment was performed at least thrice in duplicate.
Mouse recombinant Shh was obtained from R&D Systems.
Shh was dissolved in PBS with 0.1% bovine serum albumin. In each experiment, the controls and all treatments
contained all vehicles used. All treatments were conducted
in phenol red-free medium with charcoal-stripped serum
[32]. Each experiment was performed at least thrice in
duplicate.
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2.6. Plasmid. The vectors containing Gal4-luciferase, the 4x
mouse GST Ya subunit ARE (4 copies of the 41 bp GST
Ya element) reporter, hemagglutinin (HA) tagged Nrf2, and
the Nrf2 transactivation domain-Gal4 DNA binding domain
fusion vector have been described previously [25, 28, 33].
phRG-TK control renilla luciferase vector was obtained from
Promega.
2.7. Regulation of Antioxidant Response Element (Nrf2-ARE)
Assay. The transcriptional activity of NF-E2 Related Factor
2 (Nrf2) on antioxidant response element (ARE) was monitored as previously described [25]. Briefly, COS-1 cells were
seeded in 24-well plates in phenol red-free medium with
10% dextran-coated charcoal-stripped fetal bovine serum,
for transient transfection with 150 ng 4x mouse GST Ya
subunit ARE firefly luciferase reporter or Gal4-luciferase
reporter, 10 ngphRGTK control renilla luciferase vector,
and different expression vectors using plus and Lipofectamine reagents (Invitrogen, Carlsbad, CA). Constant transfected DNA amount was compensated by empty vector—
pcDNA3.1(+)zeo (Invitrogen, Carlsbad, CA). After 12–16 h,
transfected cells were then treated with bonediol or vehicle.
After 24 h of incubation, cells were rinsed with PBS twice and
lysed to measure the luciferase level using the Dual Luciferase
assay kit (Promega, Madison, WI). Data were normalized to
the cotransfected phRG-TK control renilla luciferase activity.
All experiments were performed at least three times with
duplicate samples per experiment.
2.8. Statistical Analysis. Graph Pad Prism 4 (Graph Pad
Software, La Jolla, CA) was used to calculate 𝑃 values of
𝑃 < 0.05 which were considered significant in all cases.
The IC50 were calculated using doses-response nonlinear fit
curve. One-way analysis of variance (ANOVA) was used to
assess significant differences among treated groups followed
by Dunnett’s test.

3. Results
In order to explore the possible antiproliferative effect of the
compound bonediol, a SRB assay was performed to determine whether this molecule was able to inhibit the growth of
prostate cancer cells. A typical dose-response behavior was
observed in all cell lines tested, with IC50 in the various cell
lines tested ranging from 8.5 to 20.6 𝜇M (Figure 1). Table 1
shows the median concentration that inhibited cell growth
(IC50 ) and the selectivity index of bonediol towards all cell

Table 1: Antiproliferative activity IC50 (𝜇M) and selective index of
bonediol from B. macrocarpa.
Compound
Bonediol
Docetaxel

Hek-293
33.2
1.10

Cell lines IC50 𝜇M (SI)
LNCaP
PC-3
18.1 (1.8)
15.5 (2.1)
0.23 (4.78) 0.20 (5.50)

PC3-M
13.3 (2.5)
0.08 (13.75)

100
Cell growth inhibition (% control)

2.5. Competitive Binding Assay. Proteins were synthesized
using the TNT Coupled Reticulocyte Lysate System from
Promega. In vitro transcription/translation products were
treated individually with various concentrations of [3H]17-𝛽-E2 in the absence or presence of various doses of
unlabeled competitors or unlabeled 17-𝛽-E2 overnight at 4∘ C
in order to achieve equilibrium binding. Bound and free
ligand were separated by dextran-coated charcoal. Relative
binding affinity (RBA) was determined by dividing the IC50 of
the unlabeled 17-𝛽-E2 by the IC50 of the unlabeled competitor.
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Figure 1: Bonediol inhibits cell growth on HEK-293, LNCaP, PC-3,
and PC-3M cells. Various concentrations of bonediol were used for
48 h and the effects were examined using SRB colorimetric assay.
Each experiment was performed at least thrice in duplicate. IC50
values represent the concentration of the compound at which halfmaximal inhibition we observed.

lines. Bonediol inhibited the growth of PC-3, LNCaP, and
metastatic PC-3M cell lines with selectivity compared with
Hek-293.
Shh Light II cell, an NIH 3T3 cell line stably transfected
with Gli1-dependent firefly luciferase and constitutive renilla
luciferase reporters, was used to explore the ability of bonediol to inhibit Shh pathway activation. When we tested the
model with various concentrations of bonediol (0.1, 0.5, 1, and
5 𝜇M) no significant inhibition was observed compared with
the control cyclopamine (data not shown).
We next analyzed the potential of bonediol to bind to
estrogen receptors (ER𝛼 and ER𝛽) (Figure 2). Bonediol binds
to both receptors in a dose-dependent manner; 2.5 𝜇M and
2.1 𝜇M displaced 50% of estradiol binding on ER𝛼 and ER𝛽,
respectively.
As mentioned above, the activation of the Nrf2 signaling
pathway governs the expression of ARE-driven genes. This
pathway has been associated with induction of oxidative
stress and in this study was used as a possible marker
of oxidative damage from bonediol to the cells. Bonediol
induces activation of Nrf2-ARE in transfected COS-1 cells
at 1 𝜇M (3.8-fold) and 5 𝜇M (2.8-fold) (Figure 3). The results
show that bonediol activates Nrf2-ARE signaling possibly
through induction of oxidative stress.
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Figure 2: Dose-response curves of 17𝛽-estradiol and bonediol in the radio ligand receptor binding assay using [3H]17b-estradiol and human
estrogen receptor expressed in TNT Coupled Reticulocyte Lysate System: (a) ER𝛼 and (b) ER𝛽.
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Figure 3: Bonediol activate NRF2-ARE. Relative Nrf2-ARE activation from three assays is normalized with the control group. Each
symbol is the mean ± SD. ∗∗ 𝑃 < 0.01 versus control.

4. Discussion
This study evaluated for the first time the activity of bonediol
on binding to the estrogen receptors, inhibition of the Shh
pathway, and activation of Nrf2-ARE signaling. Previous
work demonstrated the potential antiproliferative effect of
bonediol [29] and that this compound has no significant
cytotoxic activity [34]. Furthermore, bonediol does not
induce apoptosis at low doses [34]. We explored here the
antiproliferative potential of bonediol against three prostate
cancer lines (hormone sensitive (LNCaP), hormone insensitive (PC-3), and high metastatic hormone insensitive PC3M) and the possible pharmacologic mechanisms. Bonediol
has an antiproliferative effect in the three prostate cancer
cell lines, indicating that this compound could have various
pharmacologic mechanisms, both hormone-dependent and

hormone-independent. Prostate cancer has been reported to
have an altered Shh signaling as a pathway of importance in
advanced growth and this pathway has recently been shown
of interest in the search for new compounds that can inhibit
cancer [32, 35]. However, bonediol did not demonstrate
an inhibition of this signaling pathway to a concentration
of 10 𝜇M (data not shown). No further evaluations were
performed at doses, since we observed damage to the cells
without concomitant inhibition of Shh signaling. Interestingly, bonediol displaced 50% of estradiol on ER𝛼 and
ER𝛽 at concentrations of 2.1 and 2.5 𝜇M, respectively. No
studies on the estrogenic potential of alkyl catechols have
been reported previously, but there are reports of related
synthetic alkyl phenols compounds that have antiestrogenic
effect [36]. Furthermore, some studies indicate that the main
pharmacophore for recognition by the estrogen receptor is
the presence of at least one phenolic alcohol and hydrophobic
long chain [37, 38]. We do not know precisely how bonediol
is binding to the ERs, but the presence of the two phenolic
alcohols and long chain hydrophobic may be involved. The
binding of the compound bonediol to the ERs does not
indicate whether bonediol could be acting as an antagonist
or as an agonist. Further studies are required to observe the
way in which this compound could regulate either receptor.
It is known that preferential ER𝛽 activation has an antiproliferative effect in breast and prostate cells and is viewed as a
protective balance against ER𝛼 activation, which is associated
with proliferation [39–41]. Bonediol may be regulating both
ER𝛼 and ER𝛽, resulting in an antiproliferative effect on
prostate cancer. Moreover, Nelles et al. [19] remarked the
importance of development of new selective ER modulators
with therapeutic potential.
Finally, we found that bonediol activates Nrf2-ARE signaling at a concentration of 1 𝜇M (3.8-fold induction), which
is indicative of oxidative stress and may be a mechanism of
damage to the cell lines tested. However, another explanation
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for the activation of this pathway could be that some chemical
compounds with antioxidant properties have the ability to be
redox active and activate the Nrf2-ARE pathway [42]. In this
context, some related alkyl phenols have shown antioxidant
and prooxidant activity [43, 44]. Antioxidants from plants
have been studied for the prevention of several cancer types,
including prostate cancer, and it is currently believed that
small doses of these compounds could have a beneficial
effect by inducing the activation of antioxidant proteins and
detoxifying enzymes, which would act against carcinogenic
insults [23]. At a concentration of 5 𝜇M bonediol had a
slightly lower induction (2.8-fold), compared with the inductive effect at 1 𝜇M (3.8-fold). This effect could be due to the
compound exhibiting toxic effects in cell lines at the higher
concentration.
In the course of our research we found that the compound
bonediol is able to bind ER𝛼 and ER𝛽. This is the first
report of the potential estrogenic activity of these compounds
(alkyl catecohols), isolated from plants. Additionally, bonediol induces activation of Nrf2-ARE, possibly functioning as
an antioxidant and generating oxidative stress.
Future studies aimed at elucidating how this compound
binds to the estrogen receptors and the exact mechanism
by which bonediol activates Nrf2-ARE will be beneficial to
development of a potential new prostate cancer therapeutic.

5. Conclusion
In summary, we found that bonediol binds to both ER𝛼 and
ER𝛽 in the low micromolar range, has potential estrogenic
activity, and can induce Nrf2 signaling. Furthermore, we
propose that the compound bonediol may serve as a potential chemopreventive treatment with therapeutic potential
against prostate cancer.
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A. Ślusarz, N. S. Shenouda, M. S. Sakla et al., “Common
botanical compounds inhibit the hedgehog signaling pathway
in prostate cancer,” Cancer Research, vol. 70, no. 8, pp. 3382–
3390, 2010.
D. D. Zhang and M. Hannink, “Distinct cysteine residues in
Keap1 are required for Keap1-dependent ubiquitination of Nrf2
and for stabilization of Nrf2 by chemopreventive agents and
oxidative stress,” Molecular and Cellular Biology, vol. 23, no. 22,
pp. 8137–8151, 2003.

[34] R. Moo-Puc, J. Chale-Dzul, and E. Caamal-Fuentes, “Bonellia
albiflora: a mayan medicinal plant that induces apoptosis in
cancer cells,” Evidence-Based Complementary and Alternative
Medicine, vol. 2013, Article ID 823453, 8 pages, 2013.
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